Imagine a microscopic, sponge-like shield that wraps around medical tubes and heart devices. This shield slowly releases medicine for 30 days to stop bacteria from growing and blood from clotting. It works like a slow-release time capsule that keeps the device clean and safe inside the body.
Medical devices like catheters cause bloodstream infections and blood clots, leading to high patient mortality and an average cost of €30,000 per case. Current market solutions fail to prevent both complications simultaneously with a long-lasting effect.
A patented multilayered nanogel coating called CMD-COAT(TM) that releases antibacterial and antithrombotic drugs over 30 days.
If you are a catheter manufacturer dealing with high rates of bloodstream infections—which affect up to 9% of cases—this project developed CMD-COAT(TM) that provides a 30-day preventive barrier against both infection and thrombosis.
If you are a producer of implantable devices dealing with the risk of protein adsorption and fouling, this project developed a nanogel coating that can be applied to metallic, biological, or polymeric surfaces to prevent complications.
If you are an ICU equipment provider dealing with the fact that up to 37% of patients acquire infections during their stay, this project developed a bioactive coating that reduces the risk of sepsis and associated mortality.
Based on available project data, the specific cost of the coating is not mentioned, though it notes that treating one infection case costs healthcare systems an average of €30,000.
The project aims to bring the technology to market readiness through accelerated development and preclinical validation, but specific industrial scale-up metrics are not provided.
The technology is based on CMD-COAT(TM), which is described as a unique, patented bioactive coating.
The coating ensures a sustained and controlled release of active pharmaceutical ingredients over a period of 30 days.
The nanoreservoirs are deposited as a coating that can be applied to any biomaterial, including metallic, biological, or polymeric surfaces.
The consortium is highly lean and industry-focused, consisting of 2 SMEs from Belgium and Spain. With a 100% industry ratio, the partnership combines technical expertise in cardiovascular diseases and chemistry (CM4CURE SA) with business strategy and innovation management (Fresci), indicating a strong drive toward commercialization rather than academic research.
Contact CM4CURE SA in Belgium for licensing and partnership inquiries.
Contact us to connect with the Coati-X consortium for preclinical partnership opportunities.
